Creatinine News and Research RSS Feed - Creatinine News and Research

Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays. [More]
Night-time BP variability improves vascular risk prediction

Night-time BP variability improves vascular risk prediction

Measuring night-time variability in the blood pressure of patients with hypertension may help to predict their risk of having a cardiovascular event, show data from an international study. [More]
Standard risk factors stratify already high-risk diabetic patients

Standard risk factors stratify already high-risk diabetic patients

Cardiovascular disease risk factors are associated with mortality even among patients with Type 2 diabetes who are already at high risk due to having high coronary artery calcified plaque, say researchers. [More]
Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

For more than 40 years, physicians have treated diminished kidney function as two distinct syndromes: acute kidney injury (AKI) and chronic kidney disease (CKD). However, recent epidemiologic and mechanistic studies suggest the two syndromes are not distinct entities, but interconnected. [More]
Study calls for improvements in physicians' inconsistent record of ordering lab tests

Study calls for improvements in physicians' inconsistent record of ordering lab tests

Why does one physician in a walk-in practice order laboratory monitoring tests for patients more often than a colleague working down the hallway? [More]
Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4). [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
Cardiac biomarkers aid microvascular risk prediction in diabetics

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers. [More]
New therapies for kidney disease can be developed by revising definition of kidney disease

New therapies for kidney disease can be developed by revising definition of kidney disease

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests that new therapies for kidney disease could be developed more quickly by revising the definition of kidney disease progression used during clinical trials. [More]
Global risk assessment urged for hypertensive patients

Global risk assessment urged for hypertensive patients

Global risk assessment has a large impact on the risk stratification and therefore management of patients with hypertension, a study shows. [More]
FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). [More]
Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation. [More]
Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

In the UK paracetamol toxicity is the most common cause of ALF and has a high mortality rate. It is estimated that 150 to 200 deaths and 15 to 20 LTs occur as a result of poisoning each year in England and Wales. [More]
Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Siemens Healthcare and the National Kidney Foundation (NKF) announced today a new strategic alliance focusing on education, awareness and screening for kidney disease in high-risk individuals. This important collaboration will leverage the latest testing recommendations from the NKF to improve detection among the 73 million Americans at risk for kidney disease. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities. [More]
Bisphenol A may promote prostate tumourigenesis

Bisphenol A may promote prostate tumourigenesis

Bisphenol A, an organic compound that is ubiquitous in plastic products, may have a direct tumourigenic effect in the prostate, US researchers have shown. [More]
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. [More]
Nerve growth factor may be dynamic marker of OAB pathophysiology

Nerve growth factor may be dynamic marker of OAB pathophysiology

Urine levels of nerve growth factor fluctuate in line with changes in bladder pathophysiology, a 5-year study of people with overactive bladder has found. [More]
Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013. [More]